The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation
Introduction <br> HIV is a highly diverse virus with significant genetic variability which may confer biologic differences that could impact on treatment outcomes. <br> Materials and methods <br> We studied the association between HIV subtypes and immunologic and virologic outcome...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2019
|
| _version_ | 1797066075448279040 |
|---|---|
| author | Ogbenna, AA Meloni, S Inzaule, S Hamers, RL Sigaloff, K Osibogun, A Adeyemo, TA Okonkwo, P Samuels, JO Kanki, PJ Rinke de Wit, TF Akanmu, AS |
| author_facet | Ogbenna, AA Meloni, S Inzaule, S Hamers, RL Sigaloff, K Osibogun, A Adeyemo, TA Okonkwo, P Samuels, JO Kanki, PJ Rinke de Wit, TF Akanmu, AS |
| author_sort | Ogbenna, AA |
| collection | OXFORD |
| description | Introduction
<br>
HIV is a highly diverse virus with significant genetic variability which may confer biologic differences that could impact on treatment outcomes.
<br>
Materials and methods
<br>
We studied the association between HIV subtypes and immunologic and virologic outcomes in a longitudinal cohort of 169 patients on combination antiretroviral therapy. Participants were followed up for 5 years. Demographic data, CD4 cell count and viral loads (VL) were extracted from medical records. Whole protease gene and codon 1–300 of the reverse transcriptase gene were sequenced and analysed.
<br>
Results
<br>
Sixty-four percent of participants were females with a median age of 35 years. Twelve different subtypes were observed, the commonest being CRF 02_AG (55.0%) and subtypes G (23.1%). All subtypes showed steady rise in CD4 count and there was no difference in proportion who achieved CD4+ cell count rise of ≥100 cells/μL from baseline within 12 months’ post-initiation of ART, or ≥350 cells/μL at 60 months’ post-initiation. Median time to attaining a rise of ≥350 cells/μL was 24 months (6–48 months). The proportion that achieved undetectable VL at month 6 and 12 post-initiation of ART were comparable across subtypes. At end of 5th year, there was no statistical difference in proportion with virologic failure.
<br>
Conclusion
<br>
No association between HIV subtypes and immunologic or virologic response to therapy was observed, suggesting that current first-line ART may have similar efficacy across subtype predominating in South-West Nigeria. |
| first_indexed | 2024-03-06T21:37:12Z |
| format | Journal article |
| id | oxford-uuid:46a9a2d7-b44f-4e20-a95f-3819c402f260 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:37:12Z |
| publishDate | 2019 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:46a9a2d7-b44f-4e20-a95f-3819c402f2602022-03-26T15:15:06ZThe impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:46a9a2d7-b44f-4e20-a95f-3819c402f260EnglishSymplectic ElementsPublic Library of Science2019Ogbenna, AAMeloni, SInzaule, SHamers, RLSigaloff, KOsibogun, AAdeyemo, TAOkonkwo, PSamuels, JOKanki, PJRinke de Wit, TFAkanmu, ASIntroduction <br> HIV is a highly diverse virus with significant genetic variability which may confer biologic differences that could impact on treatment outcomes. <br> Materials and methods <br> We studied the association between HIV subtypes and immunologic and virologic outcomes in a longitudinal cohort of 169 patients on combination antiretroviral therapy. Participants were followed up for 5 years. Demographic data, CD4 cell count and viral loads (VL) were extracted from medical records. Whole protease gene and codon 1–300 of the reverse transcriptase gene were sequenced and analysed. <br> Results <br> Sixty-four percent of participants were females with a median age of 35 years. Twelve different subtypes were observed, the commonest being CRF 02_AG (55.0%) and subtypes G (23.1%). All subtypes showed steady rise in CD4 count and there was no difference in proportion who achieved CD4+ cell count rise of ≥100 cells/μL from baseline within 12 months’ post-initiation of ART, or ≥350 cells/μL at 60 months’ post-initiation. Median time to attaining a rise of ≥350 cells/μL was 24 months (6–48 months). The proportion that achieved undetectable VL at month 6 and 12 post-initiation of ART were comparable across subtypes. At end of 5th year, there was no statistical difference in proportion with virologic failure. <br> Conclusion <br> No association between HIV subtypes and immunologic or virologic response to therapy was observed, suggesting that current first-line ART may have similar efficacy across subtype predominating in South-West Nigeria. |
| spellingShingle | Ogbenna, AA Meloni, S Inzaule, S Hamers, RL Sigaloff, K Osibogun, A Adeyemo, TA Okonkwo, P Samuels, JO Kanki, PJ Rinke de Wit, TF Akanmu, AS The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation |
| title | The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation |
| title_full | The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation |
| title_fullStr | The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation |
| title_full_unstemmed | The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation |
| title_short | The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation |
| title_sort | impact of hiv 1 subtypes on virologic and immunologic treatment outcomes at the lagos university teaching hospital a longitudinal evaluation |
| work_keys_str_mv | AT ogbennaaa theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT melonis theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT inzaules theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT hamersrl theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT sigaloffk theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT osiboguna theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT adeyemota theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT okonkwop theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT samuelsjo theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT kankipj theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT rinkedewittf theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT akanmuas theimpactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT ogbennaaa impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT melonis impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT inzaules impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT hamersrl impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT sigaloffk impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT osiboguna impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT adeyemota impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT okonkwop impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT samuelsjo impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT kankipj impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT rinkedewittf impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation AT akanmuas impactofhiv1subtypesonvirologicandimmunologictreatmentoutcomesatthelagosuniversityteachinghospitalalongitudinalevaluation |